Home › Trials › NCT06828055

VK2735 for weight management in adults

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

PHASE2 · Viking Therapeutics, Inc. · NCT06828055

This study is testing a new oral medication called VK2735 to see if it can help adults who are overweight or obese lose weight and improve their health over 13 weeks.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment280 (estimated)
Ages18 Years and up
SexAll
SponsorViking Therapeutics, Inc. (industry)
Locations15 sites (Peoria, Arizona and 14 other locations)
Trial IDNCT06828055 on ClinicalTrials.gov

What this trial studies

This phase 2 clinical trial is a 13-week randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and weight loss efficacy of VK2735, an oral formulation, in adults who are obese or overweight with at least one weight-related co-morbid condition. Participants will receive either VK2735 or a matched placebo once daily. The study aims to assess pharmacodynamic effects and pharmacokinetics alongside weight loss outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a BMI of 27 kg/m2 or higher and at least one weight-related co-morbid condition.

Not a fit: Patients with a history of diabetes mellitus or chronic pancreatitis, or those with significant medical or psychiatric disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide an effective new option for weight management in adults struggling with obesity or overweight conditions.

How similar studies have performed: Other studies have shown promise in weight management approaches, but the specific formulation VK2735 is novel and has not been extensively tested in this context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥18 years of age at the time of signing the informed consent.
2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2

   * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
   * BMI calculated at the Screening visit will be used to determine eligibility.

Exclusion Criteria:

1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
4. Current or past diagnosis of chronic pancreatitis
5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Where this trial is running

Peoria, Arizona and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Weight Loss, Overweight Obese

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.